{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:40:29Z","timestamp":1792694429058,"version":"4.5.0"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,7,11]]},"abstract":"\n Importance<\/jats:title>\n Cytisinicline (cytisine) is a plant-based alkaloid that, like varenicline, binds selectively to \u03b14\u03b22 nicotinic acetylcholine receptors, which mediate nicotine dependence. Although not licensed in the US, cytisinicline is used in some European countries to aid smoking cessation, but its traditional dosing regimen and treatment duration may not be optimal.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the efficacy and tolerability of cytisinicline for smoking cessation when administered in a novel pharmacokinetically based dosing regimen for 6 or 12 weeks vs placebo.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A 3-group, double-blind, placebo-controlled, randomized trial (ORCA-2) compared 2 durations of cytisinicline treatment (6 or 12 weeks) vs placebo, with follow-up to 24 weeks, among 810 adults who smoked cigarettes daily and wanted to quit. It was conducted at 17 US sites from October 2020 to December 2021.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized (1:1:1) to cytisinicline, 3 mg, 3 times daily for 12 weeks (n\u2009=\u2009270); cytisinicline, 3 mg, 3 times daily for 6 weeks then placebo 3 times daily for 6 weeks (n\u2009=\u2009269); or placebo 3 times daily for 12 weeks (n\u2009=\u2009271). All participants received behavioral support.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Biochemically verified continuous smoking abstinence for the last 4 weeks of cytisinicline treatment vs placebo (primary) and from end of treatment to 24 weeks (secondary).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 810 randomized participants (mean age, 52.5 years; 54.6% female; mean of 19.4 cigarettes smoked daily), 618 (76.3%) completed the trial. For the 6-week course of cytisinicline vs placebo, continuous abstinence rates were 25.3% vs 4.4% during weeks 3 to 6 (odds ratio [OR], 8.0 [95% CI, 3.9-16.3];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and 8.9% vs 2.6% during weeks 3 to 24 (OR, 3.7 [95% CI, 1.5-10.2];\n P<\/jats:italic>\n \u2009=\u2009.002). For the 12-week course of cytisinicline vs placebo, continuous abstinence rates were 32.6% vs 7.0% for weeks 9 to 12 (OR, 6.3 [95% CI, 3.7-11.6];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and 21.1% vs 4.8% during weeks 9 to 24 (OR, 5.3 [95% CI, 2.8-11.1];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Nausea, abnormal dreams, and insomnia occurred in less than 10% of each group. Sixteen participants (2.9%) discontinued cytisinicline due to an adverse event. No drug-related serious adverse events occurred.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Both 6- and 12-week cytisinicline schedules, with behavioral support, demonstrated smoking cessation efficacy and excellent tolerability, offering new nicotine dependence treatment options.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04576949<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2023.10042","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T11:01:06Z","timestamp":1689073266000},"page":"152","source":"Crossref","is-referenced-by-count":95,"title":["Cytisinicline for Smoking Cessation"],"prefix":"10.1001","volume":"330","author":[{"given":"Nancy A.","family":"Rigotti","sequence":"first","affiliation":[{"name":"Tobacco Research and Treatment Center, Division of General Internal Medicine and Mongan Institute, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal L.","family":"Benowitz","sequence":"additional","affiliation":[{"name":"Research Program in Clinical Pharmacology, Division of Cardiology, Department of Medicine, University of California San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Prochaska","sequence":"additional","affiliation":[{"name":"Department of Medicine and Stanford Prevention and Research Center, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Leischow","sequence":"additional","affiliation":[{"name":"College of Health Solutions, Arizona State University, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Nides","sequence":"additional","affiliation":[{"name":"Los Angeles Clinical Trials, Burbank, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Blumenstein","sequence":"additional","affiliation":[{"name":"Trial Architecture Consulting, Chevy Chase, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Clarke","sequence":"additional","affiliation":[{"name":"Achieve Life Sciences, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cain","sequence":"additional","affiliation":[{"name":"Achieve Life Sciences, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Achieve Life Sciences, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"joi230068r2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMsa1211128","article-title":"21st-Century hazards of smoking and benefits of cessation in the United States.","volume":"368","author":"Jha","year":"2013","journal-title":"N Engl J Med"},{"issue":"10037","key":"joi230068r4","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1016\/S0140-6736(16)30272-0","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.","volume":"387","author":"Anthenelli","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"joi230068r5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1001\/jama.2020.23541","article-title":"Interventions for tobacco cessation in adults, including pregnant persons: updated evidence report and systematic review for the US Preventive Services Task Force.","volume":"325","author":"Patnode","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"joi230068r6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jama.2022.0395","article-title":"Treatment of tobacco smoking: a review.","volume":"327","author":"Rigotti","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"joi230068r7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMcp2032393","article-title":"Tobacco addiction.","volume":"387","author":"Selby","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"joi230068r9","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/add.v114.11","article-title":"Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation.","volume":"114","author":"Tutka","year":"2019","journal-title":"Addiction"},{"key":"joi230068r10","doi-asserted-by":"publisher","first-page":"f5198","DOI":"10.1136\/bmj.f5198","article-title":"Cytisine, the world\u2019s oldest smoking cessation aid.","volume":"347","author":"Prochaska","year":"2013","journal-title":"BMJ"},{"issue":"13","key":"joi230068r11","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1102035","article-title":"Placebo-controlled trial of cytisine for smoking cessation.","volume":"365","author":"West","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"joi230068r12","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1056\/NEJMoa1407764","article-title":"Cytisine versus nicotine for smoking cessation.","volume":"371","author":"Walker","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"joi230068r13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jama.2021.7621","article-title":"Effect of cytisine vs varenicline on smoking cessation: a randomized clinical trial.","volume":"326","author":"Courtney","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"joi230068r14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/dta.v7.6","article-title":"Pharmacokinetics of cytisine, an a4 \u00df2 nicotinic receptor partial agonist, in healthy smokers following a single dose.","volume":"7","author":"Jeong","year":"2015","journal-title":"Drug Test Anal"},{"issue":"10","key":"joi230068r15","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/ntr\/ntab073","article-title":"A multicenter, double-blind, randomized, placebo-controlled phase 2b trial of cytisinicline in adult smokers (the ORCA-1 Trial).","volume":"23","author":"Nides","year":"2021","journal-title":"Nicotine Tob Res"},{"issue":"1","key":"joi230068r16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/add.2004.99.issue-1","article-title":"Shape of the relapse curve and long-term abstinence among untreated smokers.","volume":"99","author":"Hughes","year":"2004","journal-title":"Addiction"},{"issue":"9","key":"joi230068r17","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/add.1991.86.issue-9","article-title":"The Fagerstr\u00f6m test for nicotine dependence: a revision of the Fagerstr\u00f6m Tolerance Questionnaire.","volume":"86","author":"Heatherton","year":"1991","journal-title":"Br J Addict"},{"issue":"5","key":"joi230068r18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/occmed\/kqu024","article-title":"The Hospital Anxiety and Depression Scale.","volume":"64","author":"Stern","year":"2014","journal-title":"Occup Med (Lond)"},{"issue":"12","key":"joi230068r19","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"3","key":"joi230068r20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/add.2005.100.issue-3","article-title":"Outcome criteria in smoking cessation trials: proposal for a common standard.","volume":"100","author":"West","year":"2005","journal-title":"Addiction"},{"issue":"3","key":"joi230068r21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00213-009-1742-x","article-title":"Is the ten-item Questionnaire of Smoking Urges (QSU-brief) more sensitive to abstinence than shorter craving measures?","volume":"208","author":"West","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"joi230068r22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/14622200020032051","article-title":"Evaluation of the brief Questionnaire of Smoking Urges (QSU-brief) in laboratory and clinical settings.","volume":"3","author":"Cox","year":"2001","journal-title":"Nicotine Tob Res"},{"key":"joi230068r23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/rssb.1995.57.issue-1","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"issue":"20","key":"joi230068r24","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1002\/sim.3639","article-title":"Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?","volume":"28","author":"Liu","year":"2009","journal-title":"Stat Med"},{"key":"joi230068r25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/01621459.1977.10479909","article-title":"A table of exact confidence limits for differences and ratios of two proportions and their odds ratio.","volume":"72","author":"Thomas","year":"1977","journal-title":"J Am Stat Assoc"},{"key":"joi230068r26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jama.296.1.56","article-title":"A randomized controlled trial comparing the efficacy of varenicline, a novel a4\u00df2 nicotinic acetylcholine receptor partial agonist, to bupropion and to placebo for smoking cessation.","volume":"296","author":"Jorenby","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"joi230068r27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1161\/CIRCULATIONAHA.109.869008","article-title":"Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial.","volume":"121","author":"Rigotti","year":"2010","journal-title":"Circulation"},{"issue":"5","key":"joi230068r28","article-title":"Nicotine receptor partial agonists for smoking cessation.","volume":"5","author":"Livingstone-Banks","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"joi230068r29","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jtho.2022.07.007","article-title":"Cytisine Therapy Improved Smoking Cessation in the Randomized Screening and Multiple Intervention on Lung Epidemics Lung Cancer Screening Trial.","volume":"17","author":"Pastorino","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"10","key":"joi230068r30","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1111\/add.v116.10","article-title":"Cytisine versus varenicline for smoking cessation in New Zealand indigenous Maori: a randomized controlled trial.","volume":"116","author":"Walker","year":"2021","journal-title":"Addiction"},{"key":"joi230068r1","volume-title":"WHO Report on the Global Tobacco Epidemic, 2019: Monitoring Tobacco Use and Prevention Policies","author":"World Health Organization","year":"2019"},{"key":"joi230068r3","volume-title":"Smoking Cessation: A Report of the Surgeon General\u2014 Executive Summary","author":"US Department of Health and Human Services","year":"2020"},{"key":"joi230068r8","unstructured":"US Food and Drug Administration. Accessed August 15, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021928_s000_ChantixTOC.cfm"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2807079\/jama_rigotti_2023_oi_230068_1688654415.02609.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T11:01:10Z","timestamp":1689073270000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2807079"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,7,11]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.10042","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,11]]}}}